epocrates logo
epocrates logo
epocrates logo
  • 0
Journal Article Synopsis

N Engl J Med

EULAR 2026: New biologic halves flare risk in IgG4-related disease

June 10, 2026

card-image
Phase 3 INDIGO trial shows obexelimab reduces flares while sparing steroids. . .
learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information